Search

PRINCIPAL SCIENTIST, CANCER EPIGENETICS - PFIZER INC. - LA JOLLA, CA

Work collaboratively with computational biology group to integrate complex data sets including epigenomic and other ‘omic' data in...

PRINCIPAL SCIENTIST, CANCER EPIGENETICS - PFIZER - LA JOLLA, CA

Work collaboratively with computational biology group to integrate complex data sets including epigenomic and other ‘omic' data in...

 
 
 
Notes from the JPM19 Vortex: Price Apocalypse, Celgene Fallout & More

NOTES FROM THE JPM19 VORTEX: PRICE APOCALYPSE, CELGENE FALLOUT & MORE

[ Editor's note: Ben Fidler and Sarah de Crescenzo coauthored this report .] It is here, and then it is gone. But by the time everyone...

The drugmaker famous for Viagra has a new strategy for fighting cancer that could generate $5 billion a year. We got a look inside

THE DRUGMAKER FAMOUS FOR VIAGRA HAS A NEW STRATEGY FOR FIGHTING CANCER THAT COULD GENERATE $5 BILLION A YEAR. WE GOT A LOOK INSIDE

Developing drugs to treat cancer is a major part of pharmaceutical giant Pfizer's future strategy. Pfizer already has a presence in...

 
 
 
Big Pharma ushers in new year with price hikes on hundreds of drugs

BIG PHARMA USHERS IN NEW YEAR WITH PRICE HIKES ON HUNDREDS OF DRUGS

Enlarge / Ian Read, chairman and CEO of Pfizer Inc. spoke with President Trump last July about pausing drug price hikes. Pfizer now...

Bio Roundup: 2019 Trials, Pilgrim Price Chat, Pre-Xmas Sales & More

BIO ROUNDUP: 2019 TRIALS, PILGRIM PRICE CHAT, PRE-XMAS SALES & MORE

It's beginning to look a lot like, well, the last roundup of the year, with plenty of news to pack in before our holiday breather....

 
 
 
Pharma giant GlaxoSmithKline signs mega deal with Pfizer that could change the face of global healthcare

PHARMA GIANT GLAXOSMITHKLINE SIGNS MEGA DEAL WITH PFIZER THAT COULD CHANGE THE FACE OF GLOBAL HEALTHCARE

British pharmaceuticals giant GlaxoSmithKline will combine its consumer health business into a joint venture with US rival Pfizer to...

15 For '19: Key Clinical Data to Watch For Next Year

15 FOR '19: KEY CLINICAL DATA TO WATCH FOR NEXT YEAR

On Monday, Xconomy began our annual look ahead at clinical trials that could define biotech and have profound healthcare effects in...

 
 
 
Kineta Gets $15M in New Cancer Drug Partnership with Pfizer

KINETA GETS $15M IN NEW CANCER DRUG PARTNERSHIP WITH PFIZER

Seattle biotech company Kineta continues to expand its roster of drug development partners, announcing on Monday it has entered into...

15 For '19: Key Clinical Data To Watch For Next Year

15 FOR '19: KEY CLINICAL DATA TO WATCH FOR NEXT YEAR

It can take decades and billions of dollars to develop a drug, and its fate-and often that of its developer-rests in the outcome of...

 
 
 

ALS-FOCUSED QURALIS RAISES $5.5M IN SEED MONEY, WINS PFIZER TICKET TO LABCENTRAL

Neurodegenerative disease startup QurAlis has extended the seed round it first announced in April, bringing its total funding up to...

Former pharma executive who joined HHS to help lower drug prices found bludgeoned to death in D.C.. ruled "suicide"

FORMER PHARMA EXECUTIVE WHO JOINED HHS TO HELP LOWER DRUG PRICES FOUND BLUDGEONED TO DEATH IN D.C.. RULED "SUICIDE"

A former executive for Pfizer, recently tasked with joining HHS to help reduce the prices of Big Pharma's monopoly prescription medications,...

 
 
 
Bio Roundup: Moderna's IPO, Arena's Comeback, E-Cig Survey & More

BIO ROUNDUP: MODERNA'S IPO, ARENA'S COMEBACK, E-CIG SURVEY & MORE

Thanksgiving is around the corner and this week delivered a bounty of deals that have a number of life science companies expressing...

BIG PHARMA RIVALS PFIZER AND NOVARTIS TEAM UP ON NASH COMBO TARGETS

Pfizer is joining forces with Novartis with a "throw it all at the wall and see what sticks" approach as they look to combine NASH...

 
 
 
Bio Roundup: Alzheimer's Puzzle, ESMO Assessed, Drug Prices & More

BIO ROUNDUP: ALZHEIMER'S PUZZLE, ESMO ASSESSED, DRUG PRICES & MORE

In the biotech investment and research communities this week, much of the attention was turned to Europe. Munich, Germany, hosted the...

Pfizer, Lilly's Study for Tanezumab Demonstrated Improvement in Pain and Function in Osteoarthritis Patients

PFIZER, LILLY'S STUDY FOR TANEZUMAB DEMONSTRATED IMPROVEMENT IN PAIN AND FUNCTION IN OSTEOARTHRITIS PATIENTS

NewsOver half of patients treated with Tanezumab reported a 50 percent or greater reduction in osteoarthritis pain. Contributed Author:...

 
 
 
Bio Roundup: Prices on TV, Novartis Hearts Radio, Warp Drive's End

BIO ROUNDUP: PRICES ON TV, NOVARTIS HEARTS RADIO, WARP DRIVE'S END

Two new battlegrounds emerged this week in the nation's ongoing drug pricing debate. The first involved television: The federal government...

 
 
 
Pfizer's CEO is stepping down after 8 years - meet the man who will be replacing him

PFIZER'S CEO IS STEPPING DOWN AFTER 8 YEARS - MEET THE MAN WHO WILL BE REPLACING HIM

Pfizer CEO Ian Read is stepping down at the end of 2018, ending his eight-year tenure at the head of the pharma giant. He'll be replaced...